Melanoma-associated antigen recognized by T cells 1 (MART-1) (MART-1)

Melanoma-associated antigen recognized by T cells 1 (MART-1), also known as Melan-A, is a lineage-specific protein primarily expressed in melanocytes and melanoma cells [1, 7]. It is a transmembrane protein localized to melanosomes, where it is essential for the maturation and structural integrity of these organelles involved in melanin production [1, 9]. In clinical oncology, MART-1 serves as a prominent tumor-associated antigen (TAA) and is a major target for immunotherapies, including peptide-based vaccines and adoptive cell transfers such as T-cell receptor (TCR) engineered T cells [2, 11]. These therapeutic approaches leverage the fact that MART-1 fragments are presented by MHC class I molecules (specifically HLA-A*02:01) on the surface of melanoma cells, allowing MART-1-specific cytotoxic T lymphocytes to recognize and destroy the tumor [2, 4]. However, because MART-1 is also expressed in normal melanocytes in the skin, eye, and inner ear, targeting this antigen can result in autoimmune-like side effects such as vitiligo, uveitis, and hearing loss [2, 10]. Despite these challenges, MART-1 remains a critical focus for developing targeted immunotherapies for metastatic melanoma [1, 5].

Other names

Melan-AMLANAMART1Antigen LB39-AAAntigen SK29-AAProtein Melan-A

Antigen presentation via MHC class I (HLA-A2) to T-cell receptors, leading to activation of cytotoxic T lymphocytes and subsequent tumor cell lysis.